Physician profile
Rakesh Amin
NPI 1437445475
$2,995,171.65
in general payments reported to CMS, 2019-2025
34 companies · $879K in 2025
The $879K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201K · 2020: $117K · 2021: $149K · 2022: $367K · 2023: $547K · 2024: $735K · 2025: $879K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.4M · Travel and Lodging: $380K · Consulting Fee: $219K · Honoraria: $109K · Food and Beverage: $60K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,392,115.50 |
| Travel and Lodging | $380,044.72 |
| Consulting Fee | $218,650.25 |
| Honoraria | $108,750.00 |
| Food and Beverage | $60,019.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $553,835.98 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $460,570.60 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $342,660.66 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $320,113.11 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320,068.76 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $302,713.11 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $248,830.47 | 2019-2025 | Spravato, Invega, Invega Sustenna |
| Allergan, INC. | $134,833.91 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $122,178.91 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $100,528.82 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $40,153.43 | 2022-2024 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $24,671.12 | 2021-2024 | Qelbree, Qelbree |
| Eisai INC. | $8,341.57 | 2020-2022 | |
| Bioxcel Therapeutics, INC. | $5,237.65 | 2023 | Igalmi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,955.91 | 2019-2025 | Abilify Asimtufii, Rexulti, Rejoyn |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,070.88 | 2021-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $1,288.21 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $639.32 | 2021-2024 | Nuplazid |
| Corium, LLC | $390.95 | 2022-2023 | Azstarys, Azstarys |
| Lundbeck LLC | $289.91 | 2019-2023 | Brintellix |
| Vanda Pharmaceuticals INC. | $275.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.33 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.15 | 2020-2023 | Trintellix |
| Biogen, INC. | $201.53 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $193.02 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $183.40 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $168.24 | 2019-2022 | |
| Neos Therapeutics, Lp | $109.37 | 2019-2023 | Adzenys Xr-Odt |
| Braeburn INC. | $57.67 | 2025 | Brixadi |
| Merck Sharp & Dohme LLC | $53.55 | 2020-2023 | Belsomra |
| Sage Therapeutics, LLC | $51.50 | 2021 | |
| Tris Pharma INC | $48.45 | 2023 | Dyanavel Xr |
| Validus Pharmaceuticals LLC | $20.55 | 2019 | |
| Neuronetics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.